Gainers
- Kanzhun Limited BZ shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share.
- Novan, Inc. NOVN shares jumped 73.3% to $15.67 after the company reported the B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved statistical significance for the primary endpoint and no serious adverse events were reported.
- Janux Therapeutics, Inc. JANX gained 46.7% to $24.93 as the company priced its IPO at $17 per share.
- Urban One, Inc. UONE gained 37.1% to $21.19, amid a continued run up into Juneteenth, during which the stock saw a surge last year.
- Iconix Brand Group, Inc. ICON surged 27.7% to $3.13.
- TaskUs, Inc TASK gained 26.8% to $29.17 after the company priced its IPO at $23 per share.
- Aptinyx Inc. APTX shares climbed 24.8% to $4.0050 on continued strength. The stock spiked Thursday after traders circulate a TipRanks titled '2 "Strong Buy" Penny Stocks That Could Rally to $10 (or More)' mentioning the stock.
- GBS Inc. GBS rose 24.5% to $4.52 after jumping around 19% on Thursday.
- Vaxart, Inc. VXRT gained 22.3% to $8.77 after Piper Sandler initiated coverage on the stock with an Overweight rating and $18 price target.
- Cassava Sciences, Inc. SAVA rose 19.1% to $79.02. Cassava Sciences shares traded higher on Monday following FDA approval for Biogen's Alzheimer's candidate.
- Carver Bancorp, Inc. CARV gained 20.3% to $14.96 amid a continued run up into Juneteenth, during which the stock saw a surge last year.
- Amesite Inc. AMST rose 18.6% to $3.2850 after surging over 25% on Thursday.
- Broadway Financial Corporation BYFC gained 18.3% to $3.02.
- Xinyuan Real Estate Co., Ltd. XIN gained 17.7% to $3.45. Xinyuan Real Estate shares gained 14% on Thursday after the company highlighted completion of five newly constructed properties.
- Protagonist Therapeutics, Inc. PTGX gained 17.5% to $39.76 after the company announced updated results from the ongoing Phase 2 study of rusfertide at the European Hematology Association 2021 Virtual Congress.
- Apollo Medical Holdings, Inc. AMEH surged 17.5% to $47.25 after it was announced the company is set to join the S&P SmallCap 600.
- AcuityAds Holdings Inc. ATY gained 15.2% to $11.77. The company priced its IPO at $10.15 per share.
- Chemomab Therapeutics Ltd. CMMB rose 14.6% to $22.92 after gaining around 4% on Thursday.
- Siebert Financial Corp. SIEB gained 14.7% to $5.31.
- Annovis Bio, Inc. ANVS jumped 14% to $88.76. Annovis Bio recently announced preliminary data demonstrating that ANVS401 protects certain nerve cells from dying after being infected by gingipains, which has a potential role in developing Alzheimer's Disease.
- Synaptogenix, Inc. SNPX gained 12.5% to $9.00. Synaptogenix recently announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer's disease (AD).
- Senseonics Holdings, Inc. SENS rose 11.9% to $4.05 after jumping 18% on Thursday.
- Protagenic Therapeutics, Inc. PTIX rose 9% to $2.91 after jumping over 13% on Thursday. Recently, the company’s S-3 filing showed registration for a $100 million mixed securities shelf offering.
- Precigen, Inc. PGEN shares rose 5% to $7.34 after the company announced the primary endpoint of both the Phase 1b AG019 monotherapy and the Phase 2a AG019 combination therapy was met from the Phase 1b/2a study of AG019 ActoBiotics.
Check out these big penny stock gainers and losers
Losers
- Recon Technology, Ltd. RCON shares dipped 58% to $5.35.
- Recon Technology reports its Beijing BHD Petrolume subsidiary signed 2 contracts with Sinopec's North China E&P Co.
- Orphazyme A/S ORPH fell 51% to $10.31 after jumping 302% on Thursday. On May 7, in the latest press statement put out by Orphazyme, it said its application for arimoclomol, which will be branded as MIPLYFFA for Niemann-Pick disease type C, is under priority review with the U.S. Food and Drug Administration — with the expected Prescription Drug User Fee Act action date of June 17.
- Curis, Inc. CRIS dipped 36.1% to $8.11 after the company announced updated data from its ongoing Phase 1/2 open-label, single arm, dose escalation and expansion trial of CA-4948.
- Aptose Biosciences Inc. APTO dropped 30.7% to $3.83 after the company released highlights from its Luxeptinib clinical program.
- Galecto, Inc. GLTO shares fell 26.5% to $5.88 after surging 60% on Thursday.
- TRxADE HEALTH, Inc. MEDS shares fell 24.1% to $5.06. Trxade Health shares climbed 63% on Thursday after the company announced the launch of its MedCheks health passport app for iOS devices.
- Heat Biologics, Inc. HTBX shares fell 23.5% to $7.33. Heat Biologics shares surged 40% on Thursday after the company filed for a patent titled “GP96-Based Cancer Therapy.”
- Antelope Enterprise Holdings Limited AEHL dropped 22.2% to $3.19 after the company announced pricing of a registered direct offering.
- Sphere 3D Corp. ANY fell 21.2% to $2.5301. Sphere 3D shares surged over 60% on Thursday on continued strength after the company and Gryphon Digital on Wednesday announced an agreement to purchase 250,000 Certified Emission Reductions.
- Forma Therapeutics Holdings, Inc. FMTX dipped 19.4% to $22.61 after the company highlighted the presentation of new Phase 1 data on etavopivat at the European Hematology Association 2021 Virtual Congress.
- Puhui Wealth Investment Management Co., Ltd. PHCF fell 17.3% to $4.36.
- Medley Management Inc. MDLY shares fell 16.9% to $6.64. Medley Management shares jumped around 37% on Thursday as retail traders pushed the stock higher.
- Qumu Corporation QUMU dipped 14.5% to $3.95 after Craig-Hallum downgraded the stock from Buy to Hold and announced a $6 price target.
- Biomerica, Inc. BMRA fell 14.5% to $3.96.
- Cheetah Mobile Inc. CMCM dropped 14.5% to $2.36 after the company reported a sharp decline in quarterly sales.
- Loop Industries, Inc. LOOP fell 14.4% to $11.77.
- ZIVO Bioscience, Inc. ZIVO fell 13.3% to $4.5190 after jumping around 6% on Thursday.
- Jiuzi Holdings, Inc. JZXN fell 13.1% to $8.25.
- Vertex Pharmaceuticals Incorporated VRTX fell 9.4% to $196.33 after the company reported it "will not advance VX-864 into late-stage development and instead will advance additional novel small."
- Tyme Technologies, Inc. TYME fell 9.3% to $1.4429 as the company announced a breast cancer trial with Georgetown University named OASIS. Enrollment is expected to start in Q3 of 2021.
- Orbsat Corp. OSAT fell 8.2% to $5.80 after jumping around 25% on Thursday.
- Aethlon Medical, Inc. AEMD fell 6.5% to $6.45. Aethlon Medical shares fell 36% on Thursday after the company announced a 1.38 million share registered direct offering priced at $9 per share..
AEMDAethlon Medical Inc
$0.6558-1.38%
AMSTAmesite Inc
$3.382.74%
ANVSAnnovis Bio Inc
$4.91-3.91%
ANYSphere 3D Corp
$0.99001.13%
APTOAptose Biosciences Inc
$0.1996-2.82%
BMRABiomerica Inc
$0.6000-0.32%
BYFCBroadway Financial Corp
$9.4920.6%
BZKanzhun Ltd
$14.703.09%
CARVCarver Bancorp Inc
$1.851.09%
CMCMCheetah Mobile Inc
$4.73-2.67%
CMMBChemomab Therapeutics Ltd
$2.10-0.94%
CRISCuris Inc
$3.471.10%
GLTOGalecto Inc
$5.835.99%
ICONIcon Energy Corp
$0.5200-3.70%
JANXJanux Therapeutics Inc
$44.11-1.08%
JZXNJiuzi Holdings Inc
$1.7613.6%
LOOPLoop Industries Inc
$1.181.72%
PGENPrecigen Inc
$1.350.75%
PTGXProtagonist Therapeutics Inc
$37.69-0.29%
PTIXProtagenic Therapeutics Inc
$0.4111-2.12%
RCONRecon Technology Ltd
$2.481.22%
SAVACassava Sciences Inc
$2.51-0.79%
SENSSenseonics Holdings Inc
$1.108.93%
SIEBSiebert Financial Corp
$3.00-2.28%
SNPXSynaptogenix Inc
$3.460.29%
TASKTaskUs Inc
$16.64-2.75%
UONEUrban One Inc
$1.492.76%
VRTXVertex Pharmaceuticals Inc
$439.62-0.03%
VXRTVaxart Inc
$0.79993.92%
XINXinyuan Real Estate Co Ltd
$2.983.11%
ZIVOZivo Bioscience Inc
$18.887.24%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in